Pricing Log in Create free account
Saturday 17 October 2026 Export LLY’s income statement to Excel — free account

Eli Lilly and Company

LLY Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.

1,257.03 5.42 +0.43%
Market cap
$1.18T
P/E
42.2×
Fwd P/E
33.1×
Dividend yield
0.53%
F-score
7/9
Altman Z
8.61
Beneish M
−1.91
Dividend safety
86/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Eli Lilly and Company (LLY) EV/EBITDA

Alert me on EV/EBITDA

As of 16 October 2026, Eli Lilly and Company (LLY) trades at a EV/EBITDA of 32.7×. Over the past ten years it has ranged from 16.9× (December 2016) to 93.6× (October 2024); the current reading is higher than 69% of that period. That is above the Drug Manufacturers General industry median of 13.8× and above the Healthcare sector median of 9.2×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 35.3× (28.22%)
FY2024 49.2× (28.67%)
FY2023 69.0× 73.88%
FY2022 39.7× 19.01%
FY2021 33.3× 48.09%
FY2020 22.5× 3.21%
FY2019 21.8× (7.08%)
FY2018 23.5× (7.91%)
FY2017 25.5× 49.17%
FY2016 17.1× (24.37%)

Quarterly newest first

Period EV/EBITDA Change
Jun 2026 31.2× 22.15%
Mar 2026 25.6× (27.59%)
Dec 2025 35.3× 20.20%
Sep 2025 29.4× (25.39%)
42 more quarters

Against its own ten years

Low 16.9× High 93.6×
Ten-year median 26.7×
Current reading's percentile 69

EV/EBITDA against peers

Company EV/EBITDA
PFE Pfizer Inc. compare 10.8×
AZN AstraZeneca PLC compare 13.8×
NVS Novartis AG compare 14.5×
AMGN Amgen Inc. compare 16.8×
JNJ Johnson & Johnson compare 18.1×
ABBV AbbVie Inc. compare 22.2×
MRK Merck & Co., Inc. compare 29.5×
LLY Eli Lilly and Company 32.7×
GILD Gilead Sciences, Inc. compare 829×
Drug Manufacturers General industry median 13.8×
Healthcare sector median 9.2×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on LLY